CoChat

Glycaemic thresholds for counterregulatory hormone and symptom responses to hypoglycaemia in people with and without type 1 diabetes: a systematic review

Open access
Verhulst, Clementine E. M., Fabricius, Therese W., Teerenstra, Steven, Kristensen, Peter L., Tack, Cees J., McCrimmon, Rory J., Heller, Simon, Evans, Mark L., Amiel, Stephanie A., Pedersen-Bjergaard, Ulrik, de Galan, Bastiaan E., on behalf of the Hypo-RESOLVE consortium · 2022 · Diabetologia

The DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index; 15 of the 47 sources its claims cite were checked for support.

Abstract

The physiological counterregulatory response to hypoglycaemia is reported to be organised hierarchically, with hormone responses usually preceding symptomatic awareness and autonomic responses preceding neuroglycopenic responses. To compare thresholds for activation of these responses more accurately between people with or without type 1 diabetes, we performed a systematic review on stepped hyperinsulinaemic–hypoglycaemic glucose clamps. A literature search in PubMed and EMBASE was conducted. We included articles published between 1980 and 2018 involving hyperinsulinaemic stepped hypoglycaemic glucose clamps among people with or without type 1 diabetes... A total of 63 articles were included, whereof 37 papers included participants with type 1 diabetes (n=559) and 51 papers included participants without diabetes (n=733)... The glycaemic thresholds for eliciting hormone responses all occurred at lower glucose levels in people with diabetes than in those without diabetes (all p<0.01): 3.8 (3.2–4.2) vs 3.4 (2.8–3.9) mmol/l for adrenaline; 3.2 (3.2–3.7) vs 3.0 (2.8–3.1) mmol/l for noradrenaline; 3.5 (3.2–4.2) vs 2.8 (2.8–3.4) mmol/l for cortisol and 3.8 (3.3–3.8) vs 3.2 (3.0–3.3) mmol/l for growth hormone.

Overview

CoChat Summary

TL;DR

This systematic review of stepped hyperinsulinaemic–hypoglycaemic clamps found that people with type 1 diabetes have lower glycaemic thresholds for counterregulatory hormone and symptom responses than people without diabetes. Within each group, autonomic and neuroglycopenic symptom thresholds were similar.

Key findings

  • Across 63 included articles, median (IQR) thresholds in people with type 1 diabetes vs without diabetes were lower for adrenaline (3.4 [2.8–3.9] vs 3.8 [3.2–4.2] mmol/l), noradrenaline (3.0 [2.8–3.1] vs 3.2 [3.2–3.7] mmol/l), cortisol (2.8 [2.8–3.4] vs 3.5 [3.2–4.2] mmol/l) and growth hormone (3.2 [3.0–3.3] vs 3.8 [3.3–3.8] mmol/l) (all p≤0.01).
  • Symptom responses were also elicited at lower glucose levels in type 1 diabetes: autonomic symptoms 3.0 (2.8–3.4) vs 3.4 (3.4–3.4) mmol/l (p=0.01) and neuroglycopenic symptoms 3.0 (3.0–3.1) vs 3.4 (2.8–N/A) mmol/l (p=0.007).
  • Autonomic and neuroglycopenic symptom thresholds did not differ from each other within either people with type 1 diabetes or people without diabetes.
  • Neither diabetes duration nor HbA1c was associated with glycaemic thresholds for any measured hormone or symptom response; glucagon thresholds in type 1 diabetes were excluded because responses were often absent or not provided (n=58).

Methods

  • Systematic review of PubMed and EMBASE (November 2018) for English-language articles published 1980–2018 involving hyperinsulinaemic stepped hypoglycaemic glucose clamps in people with or without type 1 diabetes; PROSPERO registration CRD42019120083.
  • From 3887 identified articles, 547 full texts assessed, 383 included in the prior systematic review, 108 reported stepped clamps, and 63 articles were included after exclusions; thresholds were extracted or calculated as the glucose level at which the response exceeded the 95% CI of the mean baseline measurement or euglycaemic control clamp.
  • Because thresholds were interval-censored, results are median and IQR, compared using generalised logrank tests for interval-censored data; Cox regression assessed HbA1c and diabetes duration. Symptom scores were classified as autonomic or neuroglycopenic, and whole-blood glucose values were converted to plasma values assuming plasma glucose was 11.1% higher.

Limitations

  • The paper states that threshold calculation depends on the level, number and spacing of glycaemic plateaus and on participant numbers, none of which were consistent across studies; high insulin doses in most clamps may affect counterregulatory responses; and whole-blood-to-plasma conversion may differ under hyperinsulinaemia and hypoglycaemia because of haematocrit.
  • The paper states that glucagon thresholds in type 1 diabetes could not be investigated because most studies did not report them or described absent/variable responses, and that the included studies had relatively few participants with very short or very long diabetes duration and a narrow age range, limiting detection of age or duration effects.
  • Evident from the text: there was considerable methodological variation across articles, and the review relies on experimental stepped-clamp data rather than spontaneous hypoglycaemia in clinical practice.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1007/s00125-022-05749-8

Cites

79 of 79 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Median glycaemic thresholds for counterregulatory hormone release and symptom responses to hypoglycaemia in people with or without type 1 diabetes. Data are presented as median with IQR. The numbers below the x-axis indicate the number of studies (participants). *p<0.05, **p<0.01, ***p<0.001
Fig. 1 Median glycaemic thresholds for counterregulatory hormone release and symptom responses to hypoglycaemia in people with or without type 1 diabetes. Data are presented as median with IQR. The numbers below the x-axis indicate the number of studies (participants). *p<0.05, **p<0.01, ***p<0.001CC BY · PubMed Central
Fig. 2 The glycaemic thresholds for the release of the counterregulatory hormones adrenaline (a; p=0.007), noradrenaline (b; p<0.001), cortisol (c; p<0.001) and growth hormone (d; p<0.001), and for eliciting autonomic (e; p=0.01) and neuroglycopenic (f; p=0.007) symptomatic responses are shown in non-parametric complementary cumulative distribution curves (‘survival’ curves). The p values refer to the comparison of curves of people with type 1 diabetes and without diabetes with a generalised logrank test for interval-censored survival curves. The values on the vertical axis show the probability that the threshold is larger than the corresponding value on the glucose level axis (horizontal axis)
Fig. 2 The glycaemic thresholds for the release of the counterregulatory hormones adrenaline (a; p=0.007), noradrenaline (b; p<0.001), cortisol (c; p<0.001) and growth hormone (d; p<0.001), and for eliciting autonomic (e; p=0.01) and neuroglycopenic (f; p=0.007) symptomatic responses are shown in non-parametric complementary cumulative distribution curves (‘survival’ curves). The p values refer to the comparison of curves of people with type 1 diabetes and without diabetes with a generalised logrank test for interval-censored survival curves. The values on the vertical axis show the probability that the threshold is larger than the corresponding value on the glucose level axis (horizontal axis)CC BY · PubMed Central

Verification

Claims the paper makes

9 Valid · 2 Not valid · 12 Not checked · 63 Own results and interpretations

37 more claims · 2 with their cited sources checked

Create a free account to see all 86 claims and to verify the 3 references still open.

See all claims — free account
  • Probably not a substantial claim. 18
  • It may state two separate claims as one. 33
  • The quote only partly states this claim. 2

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 79 references

Research works printed but not linked: 1

  1. Covidence (2019) Covidence - Better systematic review management. In: Cochrane. https://www.covidence.org/home. Accessed 13 Jan 2020

Cited by

See all 34

Metadata

Authors
Verhulst, C. E. M., Fabricius, T. W., Teerenstra, S., Kristensen, P. L., Tack, C. J., McCrimmon, R. J., Heller, S., Evans, M. L., Amiel, S. A., Pedersen-Bjergaard, U., de Galan, B. E., & on behalf of the Hypo-RESOLVE consortium
Affiliations
  • Radboud University Medical Center (NL)
  • Nordsjællands Hospital (DK)
  • University of Copenhagen (DK)
  • University of Dundee (GB)
  • University of Sheffield (GB)
  • University of Cambridge (GB)
  • King's College London (GB)
Corresponding author
  • Verhulst, Clementine E. M.
  • Fabricius, Therese W.
Venue
Diabetologia
Published
2022-07-22
Volume
65
Issue
10
Pages
1601-1612
ISSN
  • 0012-186X (ISSN-L)
  • 1432-0428
OpenAlex
W4286447738
Cited by
34
References
79
Citations by year
2026: 7 · 2025: 14 · 2024: 10 · 2023: 3
FWCI
0.96
Type
journal article
Language
en
Open access
Licence
Locations
  • Diabetologia (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Research Publications (Maastricht University) (publishedVersion, cc-by)
  • Discovery Research Portal (University of Dundee) (publishedVersion, cc-by)
  • Research Portal (King's College London) (publishedVersion, other-oa)
  • Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by)
  • White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
  • Radboud Repository (Radboud University) (submittedVersion, cc-by)
  • Apollo (University of Cambridge) (submittedVersion, cc-by)
  • Radboud Repository (Radboud University) (submittedVersion, other-oa)
  • Research Publications (Maastricht University) (submittedVersion, other-oa)
  • Apollo (cc-by)
  • Apollo
Funders
Horizon 2020 Framework Programme (777460)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
Keywords
hypoglycemia, type 1 diabetes, counterregulatory response, epinephrine, norepinephrine, cortisol, growth hormone, autonomic responses, hypoglycaemic symptoms, interval-censored data, autonomic dysfunction
MeSH terms
Blood Glucose, Diabetes Mellitus, Type 1, Epinephrine, Female, Humans, Hydrocortisone, Hypoglycemia, Hypoglycemic Agents, Insulin, Male, Norepinephrine, Growth Hormone

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Glycaemic thresholds for counterregulatory hormone and symptom responses to hypoglycaemia in people with and without type 1 diabetes: a systematic review. https://app.cochat.ai/papers/10.1007/s00125-022-05749-8
The paper
Verhulst, C. E. M., Fabricius, T. W., Teerenstra, S., Kristensen, P. L., Tack, C. J., McCrimmon, R. J., Heller, S., Evans, M. L., Amiel, S. A., Pedersen-Bjergaard, U., de Galan, B. E., & on behalf of the Hypo-RESOLVE consortium. (2022). Glycaemic thresholds for counterregulatory hormone and symptom responses to hypoglycaemia in people with and without type 1 diabetes: a systematic review. Diabetologia. https://doi.org/10.1007/s00125-022-05749-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.